glp-1 for dementia In New Trials, Ozempic's 'Miracle Drug' Image Takes a Hit CKD Dementia Risk Reduced with

Its agonists may provide new therapeutic directions for metabolic diseases, while studies on antagonists help us understand the inhibitory effects of GPER under pathological conditions

Peptides including Tesamorelin, AOD-9604, Tesofensine, FTPP, and MOTS-c are highlighted, and their distinct mechanismssuch as promoting lipolysis, enhancing metabolic efficiency, and controlling appetiteare described

All animal studies were conducted with the approval of the ethics committee of USTC

Both conditions improve significantly when patients lose 5-10% of body weight, making GLP-1 therapy a clinically sensible intervention even at lower BMI levels